FL-EIGHT-SLEEP
18.3.2022 17:02:08 CET | Business Wire | Press release
Eight Sleep , the world's first sleep fitness company, today announced that the Mercedes-AMG Petronas Formula 1 Team has named the company as Official Team Supplier in a joint effort to support the team’s preparations for an expansive 2022 Formula 1 schedule. The Mercedes-AMG Petronas team including drivers, Lewis Hamilton, George Russell, as well as Team Principal, Toto Wolff, will have access to Eight Sleep’s suite of products to optimize their sleep and ensure peak performance this and next season.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220318005290/en/
The Mercedes-AMG Petronas F1 Team rigorously looks for ways to improve the performance of the car and the team. Eight Sleep’s next-generation sleep technology is engineered to support the technical and human demands of the intense 2022 F1 schedule, enabling the 8x Champions to maintain their long term success. The Mercedes-AMG Petronas F1 Team joins Eight Sleep along with more than 200 professional athletes who rely on Eight Sleep to power their recovery through the Pod Pro’s advanced thermoregulation and sleep technology.
In addition to Eight Sleep’s branding being featured on the team’s car for the inaugural Miami Grand Prix, the Eight Sleep logo will be featured on all the car covers for the duration of the season. Eight Sleep will support Mercedes-AMG Petronas F1 team members to power their performance through their innovative sleep technology Data has shown that Eight Sleep products help 49% of Eight Sleep members see an increase in their HRV of at least 10% one week after sleeping on the Pod.
With grueling schedules that consist of training, racing, and traveling, it’s critical that team members properly refuel and recover in order to perform their best. When they are pushing their bodies to their limits, in between the training, racing and hectic traveling schedules, the team needs to properly recover and refuel. Eight Sleep’s thermoregulation is designed to recharge the team to peak energy levels, which will be critical for the Mercedes-AMG Petronas Formula One Team in 2022. Additionally, the Eight Sleep App leverages the product’s sensor technology to provide daily reports on key health metrics, such as heart rate, HRV, sleeping stages, and more, giving the team the ability to build better health regimes and optimize their sleep.
“Our team is made up of over 2,000 people across Brackley and Brixworth, all of whom perform at their peak every day in a sport where every single detail matters. To achieve the level of sustained performance that is required to compete in Formula 1, we are relentless in exploring all possible optimizations, including sleep. By partnering with Eight Sleep we are looking to utilize their technology during the upcoming season while also spreading a key message about the importance of recovery when you aim for peak performance,” said Toto Wolff, Team Principal and CEO of the Mercedes-AMG Petronas F1 Team.
“Eight Sleep, and myself personally, are thrilled to partner with Mercedes-AMG Petronas Formula One and power their team’s sleep so they can continue to perform at the highest level,” said Matteo Franceschetti, Co-Founder and CEO of Eight Sleep. “Growing up in Italy, Formula One was a huge part of my life – from racing cars with my father to starting my first business taking pictures of racing cars at local tracks. Mercedes-AMG Petronas F1’s commitment to constant innovation and improvement is what we strive for at Eight Sleep. We will work together to improve the team’s sleep and recovery for a successful win at this year’s Grand Prix races.”
“We’re delighted to welcome Eight Sleep to the team and to start working with them to develop and innovate around our sleep and recovery programmes,” said Richard Sanders, Commercial Director of the Mercedes-AMG Petronas F1 Team. “Eight Sleep’s approach to reimagining sleep is very similar to how we operate. They’re obsessed with performance, the fine details and ensuring our team gets the rest they need to perform at their very best.”
The Pod Pro by Eight Sleep
The Pod Pro by Eight Sleep is the most advanced solution on the market for thermoregulation. The Pod Pro retains vital features of the original and award-winning Pod, introducing new Room Climate and Weather Response, a Comfort Blend™ Integrated Topper, GentleRise™ Wake Up Technology, and double the amount of sensors enabling new Heart Rate Variability monitoring and a Daily Health Check report. The advancements in the Pod Pro help everyone with their rest and recovery – from elite athletes to everyday consumers. The product transforms any ordinary bed into an advanced health platform that fuels both performance and longevity.
Current and former Eight Sleep athletes include Red Gerard (2018 Gold Medalist, Snowboarding), Brooke Wells (Two-time individual CrossFit Gamesathlete), Apolo Ohno (Two-Time Gold Medalist, Speed Skating), Justin Medeiros (CrossFit Champion 2021), Daniel Sturridge (English Soccer Player), Daryl Homer (2020, and 2016 Silver Medalist, Fencing), and Jane Campbell (2020 Bronze Medalist, Soccer). Eight Sleep’s athlete-investors include Alex Rodriguez (retired MLB athlete and entrepreneur), Matthew Dellavedova (2020 Bronze Medalist, Basketball), Kris Bryant (San Francisco Giants outfielder), and J.D. Martinez (Boston Red Sox outfielder).
About Eight Sleep
Eight Sleep is the world's first sleep fitness company with a mission to fuel human potential through optimal sleep. Eight Sleep leverages thermoregulation, data, and technology to restore individuals to their peak energy levels every morning. Eight Sleep was named one of Fast Company's “Most Innovative Companies of 2022” and “Most Innovative Companies of 2018,” and recognized two years in a row by TIME's “Best Inventions of the Year.” To learn more, visit eightsleep.com .
About Mercedes-AMG Petronas Formula One
Mercedes-AMG Petronas Formula One Team is the works team of Mercedes-Benz, competing at the pinnacle of motorsport – the FIA Formula One™ World Championship.
Formula One is like nothing else in the sporting sphere. It’s a demanding technical and human challenge, combining cutting-edge technologies and innovation, high-performance management and elite teamwork.
At Mercedes-AMG Petronas Formula One Team, a group of passionate and determined people work to design, develop, manufacture and race the cars driven by seven-time World Champion Lewis Hamilton and young star George Russell.
The team has set a new benchmark for F1 success during the sport’s current Hybrid era, winning consecutive Drivers’ and Constructors’ World Championships in 2014, 2015, 2016, 2017, 2018, 2019 and 2020, and the Constructors’ Championship in 2021. During those title-winning seasons, the team has scored 111 wins, 232 podium finishes, 118 pole positions, 81 fastest laps and 53 one-two finishes from 160 race starts.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220318005290/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International’s Alipay+ Connects Argentina's National QR Payment Scheme via PVS,Enabling for Cross-Border Digital Payment Nationwide at Millions of Merchants17.7.2026 12:17:00 CEST | Press release
Alipay+, a global digital payment gateway under Ant International, today announced that it will enable global travellers to make QR code payments at millions of merchants across Argentina through integration with the country's national QR payment scheme Transferencias 3.0, in partnership with PVS, a fintech company specialized in developing customized payment solutions in Latin America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717276406/en/ By connecting to Argentina's national QR payment scheme, Alipay+ now enables global travellers in the country to make convenient QR code payments at merchants nationwide. This service helps to enhance global travellers' travel experiences in Argentina, allowing them to pay seamlessly at restaurants, malls and tourist attractions. Using an Alipay+ partner payment app, they can now scan the national QR code displayed at all merchants to make cross-border payments across Argentina,
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom